Exacerbations and associated healthcare cost in patients with COPD in general practice

Autor: C.P. van Schayck, Christiaan G J Saris, P.N.R. Dekhuijzen, Niels H. Chavannes, C. van Weel, W.J.H.M. van den Bosch, Tjard Schermer
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Pulmonary and Respiratory Medicine
Male
medicine.medical_specialty
Pediatrics
Exacerbation
Implementation Science [NCEBP 3]
lcsh:Medicine
Disease
Pulmonary Disease
Chronic Obstructive
exacerbation
Internal medicine
Effective Primary Care and Public Health [EBP 3]
medicine
health care costs
Humans
In patient
Medical prescription
Aged
Netherlands
Randomized Controlled Trials as Topic
general practice
COPD
Analysis of Variance
Chi-Square Distribution
Cardiovascular diseases [NCEBP 14]
chronic obstructive
business.industry
Medical record
Data Collection
lcsh:R
Effective primary care and public health [NCEBP 7]
Middle Aged
medicine.disease
Bronchodilator Agents
Respiratory Function Tests
Pathogenesis and modulation of inflammation [N4i 1]
Antitussive Agents
Cough
General practice
Healthcare cost
Female
Seasons
Pulmonary disease
Cardiology and Cardiovascular Medicine
business
Family Practice
Zdroj: Monaldi Archives for Chest Disease, Vol 65, Iss 3 (2016)
ResearcherID
Monaldi Archives for Chest Disease, 65, 133-40
Scopus-Elsevier
Monaldi Archives for Chest Disease, 65, 3, pp. 133-40
ISSN: 2532-5264
1122-0643
Popis: Exacerbations and associated healthcare cost in patients with COPD in general practice. T.R.J. Schermer, C.G.J. Saris, W.J.H.M. van den Bosch, N.H. Chavannes, C.P. van Schayck, P.N.R. Dekhuijzen, C. van Weel. Background. Acute exacerbations are a characteristic clinical expression of chronic obstructive pulmonary dis- ease (COPD). The objective of this study was to investigate the occurrence rate, management, and healthcare costs of exacerbations in patients with COPD in Dutch general practice. Methods. Baseline data set from the COPD on Prima- ry Care Treatment (COOPT) trial was used. Details on the occurrence and management of exacerbations were col- lected by systematic medical record review for the 2-year period preceding trial inclusion. Results. The mean age of the 286 study subjects in- volved was 59.2 (SD 9.6) years, postbronchodilator FEV 1 67.1% (SD 16.2) of predicted. Following ERS criteria, sub- jects suffered from: no (26%); mild (19%); moderate (40%); or severe (15%) airflow obstruction. The overall mean and median annual exacerbation rates were 0.88 (SD 0.79) and 0.5 (IQR 1.0), respectively. Exacerbation rate was not related to severity of airflow obstruction (p=0.628). Mean annual exacerbation costs per subject were € 40, € 53, € 61 and € 92 for the respective severity subgroups (p=0.012). The increase of costs in the more severe sub- groups was mainly attributable to more physician consul- tations, diagnostic procedures, and prescription of reliever medication (e.g., bronchodilators, cough preparations). Conclusions. Occurrence of exacerbations did not de- pend on the severity of airflow obstruction, whereas the healthcare cost associated with exacerbations increased along with the severity of the disease. Monaldi Arch Chest Dis 2006; 65: 3, 133-140.
Databáze: OpenAIRE
Externí odkaz: